CN108938989A - 一种治疗骨质疏松症的覆茴精健骨散 - Google Patents
一种治疗骨质疏松症的覆茴精健骨散 Download PDFInfo
- Publication number
- CN108938989A CN108938989A CN201811226179.7A CN201811226179A CN108938989A CN 108938989 A CN108938989 A CN 108938989A CN 201811226179 A CN201811226179 A CN 201811226179A CN 108938989 A CN108938989 A CN 108938989A
- Authority
- CN
- China
- Prior art keywords
- powder
- osteoporosis
- jiangu
- group
- raspberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 36
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 33
- 235000004204 Foeniculum vulgare Nutrition 0.000 title abstract description 8
- 240000006927 Foeniculum vulgare Species 0.000 title abstract description 8
- 230000037176 bone building Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 22
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 12
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 11
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 11
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 11
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 11
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 11
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 11
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 11
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 11
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 11
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- 240000007651 Rubus glaucus Species 0.000 claims abstract 5
- 229940079593 drug Drugs 0.000 claims description 17
- 235000007129 Cuminum cyminum Nutrition 0.000 claims description 7
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 6
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 6
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 6
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 6
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- 241000510672 Cuminum Species 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 24
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000002689 soil Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- 210000000988 bone and bone Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 9
- 239000011575 calcium Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 244000235659 Rubus idaeus Species 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 241001092040 Crataegus Species 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000009750 xian ling gu bao Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 108090000573 Osteocalcin Proteins 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 244000304337 Cuminum cyminum Species 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QCBCPALLWXTPLW-SFHVURJKSA-N (2S)-2-(3,4-dihydroxyphenyl)-8,8-dimethyl-2,3,9,10-tetrahydropyrano[2,3-h]chromen-4-one Chemical compound C1([C@@H]2CC(=O)C=3C=CC4=C(C=3O2)CCC(O4)(C)C)=CC=C(O)C(O)=C1 QCBCPALLWXTPLW-SFHVURJKSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100031475 Osteocalcin Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明之目的是提供一种治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子18‑22g、小茴香14‑16g、山楂14‑16g、黄精14‑16g、益智仁18‑22g、葛根18‑22g和土炒山药18‑22g作原料药物,粉碎成过100目筛的细粉,混合均匀制成;本发明原料丰富,组分间配伍合理,制备方法简单,易生产制备,使用方便,效果好,开拓了治疗骨质疏松症药物的新途径,是治疗骨质疏松症药物上的创新,有显著经济和社会效益。
Description
技术领域
本发明涉及中药,特别是一种治疗骨质疏松症的覆茴精健骨散。
背景技术
骨质疏松症是好发于绝经后女性、老年人和慢性疾病患者的常见病、多发病,发病原因是由于全身骨量减少、骨微细结构退化导致骨脆性及骨折风险增加。近年来,骨质疏松症发病率逐渐升高,我国60岁以上的老年人中约80%患有不同程度的骨质疏松症,其中以女性患者为主。目前,临床用于预防和治疗骨质疏松症的药物主要有雌激素受体调节剂、双膦酸盐类、降钙素、氟制剂等,虽然取得了一定疗效,但长期服用不良反应大,且价格昂贵。因此,提供一种安全有效的治疗骨质疏松症的药物是必须解决的技术问题。
发明内容
针对上述情况,为克服现有技术之缺陷,本发明之目的是提供一种治疗骨质疏松症的覆茴精健骨散,可有效解决骨质疏松症治疗的用药问题。
本发明解决的技术方案是,一种治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子18-22g、小茴香14-16g、山楂14-16g、黄精14-16g、益智仁18-22g、葛根18-22g和土炒山药18-22g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
本发明原料丰富,组分间配伍合理,制备方法简单,易生产制备,使用方便,效果好,开拓了治疗骨质疏松症药物的新途径,是治疗骨质疏松症药物上的创新,有显著经济和社会效益。
具体实施方式
以下结合具体情况和实施例对本发明的具体实施方式做详细说明。
本发明可由以下实施例给出。
实施例1:本发明一种治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子18g、小茴香14g、山楂14g、黄精14g、益智仁18g、葛根18g和土炒山药18g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
实施例2:本发明一种治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子20g、小茴香15g、山楂15g、黄精15g、益智仁20g、葛根20g和土炒山药20g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
实施例3:本发明一种治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子22g、小茴香16g、山楂16g、黄精16g、益智仁22g、葛根22g和土炒山药22g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
在上述药物中,其中,
覆盆子:固精补肾,明目;治劳倦、虚劳,肝肾气虚恶寒,肾气虚逆咳嗽、痿、消瘅、泄泻、赤白浊。
小茴香:有散寒止痛,理气和胃的功效;用于寒疝腹痛,睾丸偏坠,痛经,少腹冷痛,脘腹胀痛,食少吐泻。
山楂:助消化降血脂、抗动脉粥样硬化、抑菌、抗心肌缺血,常用于消化不良、冠心病、心绞痛、高脂血症等。
黄精:具有补气养阴,健脾,润肺,益肾之功效。
益智仁:具有温脾止泻摄涎,暖肾缩尿固精之功效。
葛根:有解肌退热,透疹,生津止渴,升阳止泻之功。
土炒山药:具有滋养强壮,助消化,敛虚汗,止泻之功效。
上述药物有效组合,科学配伍,相互支持,协同增效,具有消炎、消痒、止痛、强筋健骨之功效,有效用于治疗骨质疏松症,并经实地试验和应用,取得了非常好的有益技术效果,有关资料如下:
一、动物试验:
本试验通过卵巢摘除法建立雌性大鼠去势骨质疏松动物模型,探讨覆盆子与覆茴精健骨散对去势大鼠骨质疏松模型影响。
1.实验仪器:
FA(N)/JA(N)系列电子天平,上海民桥精密仪器有限公司;HWS12型电热恒温水浴锅,上海一恒科学仪器有限公司;KDC-160HR高速冷冻离心机,科大创新股份有限公司中佳分公司;680型酶标仪,美国BIO-RAD公司;可调式移液器,上海雷勃分析仪器有限公司。
2.实验试剂:
本发明覆茴精健骨散,覆茴精健骨散大剂量(含覆盆子、益智仁、葛根、土炒山药各0.16g/ml;小茴香、山楂、黄精各20g/kg,临床剂量20倍);覆茴精健骨散中剂量(10g/kg,临床剂量10倍),覆茴精健骨散小剂量(5g/kg,临床剂量5倍);阳性药:仙灵骨葆胶囊;生理盐水,河南双鹤华利药业有限公司生产。
实验动物名称:220-240g雄性大鼠,Wistar,SPF级,山东省实验动物中心质量合格证:NO.37009200002630。
3.实验方法:
取体重220-240g雌性wistar大鼠造去势骨质疏松模型。将大鼠在动物中心饲养3-4天后,于第5天随机选取12只大鼠最为空白组,其余各组大鼠称重后腹腔注10%水合氯醛(0.3ml/100g)麻醉后腹位固定,然后从大鼠背部最末肋骨下,距脊柱约2cm交叉处剪毛,消毒后切开皮肤和背肌,切开长约1cm,切口视野可见一乳白色的脂肪团,用小镊子轻轻夹住脂肪团拉出切口外,分离脂肪团,即可见到一团细线状不规则,呈黄红色的组织,即为卵巢。剪取时先将卵巢下输卵管(包括脂肪)用细线结扎,完全摘除左侧卵巢,右侧摘除80%。术后顺势将组织放回腹腔中,缝合肌肉及皮肤造骨质疏松模型。术后精心饲养,肌肉注射青霉素80万u/kg(每只0.1ml)以防感染,连续3d,每天1次,待老鼠苏醒后饲养1-2天后称重随机分为模型组、阳性组(仙灵骨葆组给药剂量为0.5g/kg,相当于临床剂量10倍,给药体积为2ml/100g,给药浓度为0.025g/ml)覆茴精健骨散高、中、低剂量组(给药剂量依次为20g/kg、10g/kg、5g/kg,相当于临床剂量的20倍、10倍、5倍)。除模型组与空白组外其余各组每天给予相应药物灌胃,连续60天,大鼠每2周称重一次,灌胃期间观察记录食量、观察大鼠活动情况。于第58天晚上禁食不禁水,次日将大鼠放入代谢笼收集大鼠尿液,于第60天末次给药2h后摘眼球取血,分离血清。取大鼠两侧股骨,一侧置于10%福尔马林,进行病理学观察。另一侧股骨用浸透过生理盐水的纱布包裹,零下40℃冷藏,用于骨密度测定。此外取大鼠左侧胫骨,用浸透过生理盐水的纱布包裹,零下40℃冷藏,用于骨生物力学测定。
主要观察指标;血清钙(Ca)、磷(P),血清骨钙素(BGP)、尿钙、磷,尿肌酐(Cr)水平、尿羟脯氨酸(HYP)
大鼠股骨骨密度值(BMD)。
大鼠胫骨待行生物力学测定;胫骨投入10%福尔马林液中,待行常规光镜观察。
4.实验结果
4.1大鼠体重
表1覆茴精健骨散对大鼠体重的影响
注:*表示p<0.05,**表示p<0.01
由上表可以看出,与空白组比较,模型组在第7周时,体重显著升高(p<0.01),显示造模成功,与模型组相比,覆茴精健骨散高、中、低剂量组以及仙灵骨葆组在第7周可显著降低大鼠体重(p<0.01);在第9周时,覆茴精健骨散高、中、低剂量组以及仙灵骨葆组均可显著降低大鼠体重(p<0.01)。
4.2对大鼠血清及尿液生化指标影响
表2.对大鼠血清及尿液生化指标的影响
由上表可以看出,与空白组比,模型组血清Ca显著下降(p<0.01)、血清P和血清骨钙素显著升高(p<0.01);模型组尿Ca、P水平显著升高(p<0.01),尿羟脯氨酸含量显著增高(p<0.01),尿肌酐水平显著降低(p<0.01),说明造模成功。与模型组比,覆茴精健骨散高、中、低剂量组和仙灵骨葆组均可显著降低血清Ca水平(p<0.01);覆茴精健骨散高、中剂量组和仙灵骨葆组可显著降低血清P水平(p<0.01),覆茴精健骨散低剂量组可降低血清P水平(p<0.05);覆茴精健骨散高、中、低剂量组和仙灵骨葆组可显著降低血清中骨钙素水平(p<0.01);覆茴精健骨散高剂量组可显著降低尿Ca水平(p<0.01),仙灵骨葆组和覆茴精健骨散中剂量组可降低尿Ca水平(p<0.05)。覆茴精健骨散高、中、低剂量组和仙灵骨葆组可显著降低尿P水平(p<0.01);覆茴精健骨散高、中、低剂量组和仙灵骨葆组可显著降低大鼠尿羟脯氨酸含量(p<0.01);仙灵骨葆组可显著升高大鼠尿肌酐水平(p<0.01),覆茴精健骨散高、中、低剂量组可明显升高大鼠尿液中尿肌酐水平(p<0.05)。4.3对大鼠股骨骨密度及胫骨骨力学强度的影响
表4.覆茴精健骨散对大鼠股骨骨密度及胫骨骨力学强度的影响
注:*表示p<0.05,**表示p<0.01
由上表可知,与空白组比较,模型组骨密度值显著降低(p<0.01),造模成功;与模型组比较,覆茴精健骨散高、中、低剂量组以及仙灵骨葆组均能显著升高大鼠股骨骨密度值(p<0.01)。通过骨力学强度比较可以看出,模型组胫骨承受最大力度显著小于空白组(p<0.01),说明造模成功;与模型组比较,覆茴精健骨散高、中、低剂量组以及仙灵骨葆组均能显著升高大鼠胫骨最大承受力(p<0.01)。
4.4对大鼠股骨病理组织影响
表5覆茴精健骨散对大鼠股骨病理组织形态的影响
| 组别 | n | - | + | ++ | +++ |
| 空白组 | 12 | 12 | 0 | 0 | 0 |
| 模型组 | 12 | 1 | 11 | 0 | 0 |
| 阳性组 | 12 | 11 | 1 | 0 | 0 |
| 覆茴精健骨散高剂量组 | 12 | 11 | 1 | 0 | 0 |
| 覆茴精健骨散中剂量组 | 12 | 11 | 1 | 0 | 0 |
| 覆茴精健骨散低剂量组 | 12 | 10 | 2 | 0 | 0 |
“-”骨小梁丰富均匀,连续性好,结构致密。“+”轻度骨小梁数目减少,连续性较差,结构较稀疏,排列疏松,不整齐。“++”中度骨小梁数目减少,连续性差,有间断,结构较稀疏,排列疏松,不整齐。“+++”重度骨小梁数目减少,不连续,结构较稀疏,排列疏松,不整齐。
5.结论
覆茴精健骨散高、中、低剂量组对去势大鼠骨质疏松模型有较好的干预作用,为临床为临床突破骨质疏松病症提供理论依据和实验基础。
二、临床试验:
在动物试验确保安全的基础上,经临床应用效果非常好,而且用药安全,疗效稳定可靠,有关试验资料是:
1、选择病例的标准:
骨质疏松症是由于多种原因导致的骨密度和骨质量下降,骨微结构破坏,造成骨脆性增加,从而容易发生骨折的全身性骨病。凡具有上述症状者,均作为选择病例的标准。
2、诊断标准:凡在临床上具有1症状者,并经检查即可确诊患有骨质疏松症。
3、纳入标准:年龄45岁及以上;自愿参与到实验中;配合后期跟踪随访。对患者进行分组处理,本发明组(20例),患者年龄最小49岁,年龄最大62岁,平均(56.1±2.8)岁;对照组(20例),患者年龄最小的50岁,年龄最大的63岁,平均(56.3±2.6)岁。本发明组与对照组在一般资料的比较上差异无统计学意义(P>0.05)。
4、排除标准:有精神疾病史者;合并有严重疾病的患者;不能配合此次观察的患者。
5、治疗方案:对照组给予患者服用维生素D,1次/d,再对患者鼻吸入制剂鲑鱼降钙素注射液,1次/d,100U/次;本发明组在对照组的基础上加用覆茴精健骨散(均为药食同源之品),15-30g/次,2次/d。3个月后统计疗效。
6、疗效评定标准:
治愈:症状完全消失,皮肤恢复正常;有效:症状有明显改善或改善;无效:症状无改善,甚至有加重之趋势。
7、统计学处理:
按上述治疗方案,经治疗后,其中,本发明组治愈11例,有效7例,无效2例,总有效率为90%;对照组治愈2例,有效10例,无效8例,总有效率为60%;本发明组患者中,出现酸痛、肿胀等并发症的有1例,对照组中出现酸痛、肿胀等并发症的有8例,本发明组明显优于对照组,效果之好是未曾料到的,试验表明,本发明配方是治疗骨质疏松症的有效药物,具有很强的临床应用价值,开拓了治疗骨质疏松症的新途径,是治疗骨质疏松症药物上的一大创新,经济和社会效益显著。
Claims (4)
1.一种治疗骨质疏松症的覆茴精健骨散,其特征是:由以下重量计的:覆盆子18-22g、小茴香14-16g、山楂14-16g、黄精14-16g、益智仁18-22g、葛根18-22g和土炒山药18-22g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
2.根据权利要求1所述的治疗骨质疏松症的覆茴精健骨散,其特征是:由以下重量计的:覆盆子18g、小茴香14g、山楂14g、黄精14g、益智仁18g、葛根18g和土炒山药18g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
3.根据权利要求1所述的治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子20g、小茴香15g、山楂15g、黄精15g、益智仁20g、葛根20g和土炒山药20g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
4.根据权利要求1所述的治疗骨质疏松症的覆茴精健骨散,由以下重量计的:覆盆子22g、小茴香16g、山楂16g、黄精16g、益智仁22g、葛根22g和土炒山药22g作原料药物,粉碎成过100目筛的细粉,混合均匀制成。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811226179.7A CN108938989B (zh) | 2018-10-22 | 2018-10-22 | 一种治疗骨质疏松症的覆茴精健骨散 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811226179.7A CN108938989B (zh) | 2018-10-22 | 2018-10-22 | 一种治疗骨质疏松症的覆茴精健骨散 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108938989A true CN108938989A (zh) | 2018-12-07 |
| CN108938989B CN108938989B (zh) | 2020-10-30 |
Family
ID=64481071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811226179.7A Active CN108938989B (zh) | 2018-10-22 | 2018-10-22 | 一种治疗骨质疏松症的覆茴精健骨散 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938989B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129679A (zh) * | 2020-09-03 | 2022-03-04 | 华子昂 | 一种儿童专用钙片及其制备方法 |
| CN114129678A (zh) * | 2020-09-03 | 2022-03-04 | 华子昂 | 一种促进儿童补钙的中药组方 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679765A (zh) * | 2005-01-19 | 2005-10-12 | 中国人民解放军第二军医大学 | 一种可防治妇女更年期综合征或骨质疏松症的中药提取物 |
| CN101618133A (zh) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | 强阳保肾药物在制备防治骨质疏松症药物中的应用 |
| CN103751529A (zh) * | 2014-02-11 | 2014-04-30 | 王雪雁 | 治疗女性绝经后骨质疏松症的药物组合物及其制备方法 |
-
2018
- 2018-10-22 CN CN201811226179.7A patent/CN108938989B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679765A (zh) * | 2005-01-19 | 2005-10-12 | 中国人民解放军第二军医大学 | 一种可防治妇女更年期综合征或骨质疏松症的中药提取物 |
| CN101618133A (zh) * | 2008-06-30 | 2010-01-06 | 广州白云山和记黄埔中药有限公司 | 强阳保肾药物在制备防治骨质疏松症药物中的应用 |
| CN103751529A (zh) * | 2014-02-11 | 2014-04-30 | 王雪雁 | 治疗女性绝经后骨质疏松症的药物组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 吕君: ""骨质疏松症中医辩证论治分析"", 《世界最新医学信息文摘》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129679A (zh) * | 2020-09-03 | 2022-03-04 | 华子昂 | 一种儿童专用钙片及其制备方法 |
| CN114129678A (zh) * | 2020-09-03 | 2022-03-04 | 华子昂 | 一种促进儿童补钙的中药组方 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108938989B (zh) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1095610A (zh) | 治疗、预防妇科疾患的药物制剂妇病康 | |
| CN100423761C (zh) | 一种治疗骨折、跌打损伤的中药制剂 | |
| CN101352505B (zh) | 一种治疗跌打伤科接骨散 | |
| CN103861079A (zh) | 一种清热止痛消瘤中药组合物 | |
| CN1319569C (zh) | 治疗骨质疏松及骨折的中药制剂及其制备方法 | |
| CN108938989A (zh) | 一种治疗骨质疏松症的覆茴精健骨散 | |
| CN106333977B (zh) | 一种治疗骨质疏松性骨折和/或骨关节炎的天然药物组合物及其用途 | |
| CN1541676A (zh) | 一种产后补血保健药物及其制备方法和应用 | |
| US20220152162A1 (en) | Compound composition for improving bone health and preparation and application thereof | |
| CN101618129A (zh) | 一种治疗风湿骨病的中药制剂 | |
| CN103285203A (zh) | 用于预防和治疗骨折的中药组合物及其制备方法 | |
| CN103417788B (zh) | 一种治疗骨折内服中药 | |
| CN102488781A (zh) | 一种治疗风湿寒性关节痛的中药组合物 | |
| CN1140287C (zh) | 治疗脾胃疾病的口服药物 | |
| CN102961662B (zh) | 一种治疗胃溃疡的药物及其制备方法 | |
| CN115844972B (zh) | 一种用于治疗骨质疏松症的脐贴及其制备方法 | |
| CN119633090A (zh) | 一种治疗脆性骨折的蒙药复方及其应用 | |
| CN103599321A (zh) | 一种用于治疗骨质疏松症的中药组合物 | |
| CN1297305C (zh) | 一种温通化瘀、消肿生骨的中药组合物 | |
| CN100353995C (zh) | 一种具有祛风活络解毒的药物组合物 | |
| CN105232642A (zh) | 一种促进骨折愈合的中药组合物 | |
| CN1205966C (zh) | 一种接骨口服药物及其制备方法 | |
| CN107982409B (zh) | 一种治疗脊髓空洞症的中药组合物、丸剂及其制备方法 | |
| CN105770358A (zh) | 一种治疗老年性骨折的中药组合物及其制备方法 | |
| CN103110719B (zh) | 治疗肾虚精亏型骨质疏松的中药酒剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |